Day: October 3, 2021

Notice Regarding Nidec Corporation’s Board Resolution on Selection for TSE’s New “Prime Market” Segment

Notice Regarding Nidec Corporation’s Board Resolution on Selection for TSE’s New “Prime Market” Segment

KYOTO, Japan, Oct. 04, 2021 (GLOBE NEWSWIRE) — On July 9, 2021, Nidec Corporation (the “Company”) received an initial assessment result from the Tokyo Stock Exchange (TSE) regarding the listing criteria for the bourse’s new market segments, which confirmed that the Company fulfilled the requirements for listing on the bourse’s main Prime Market board. Based on these results, the Company’s board of directors resolved at its meeting held on October 3, 2021 to select to list on the Prime Market as the TSE transitions to three new market segments with tighter listing criteria, and to submit the relevant applications. Going forward, the Company will adhere to the prescribed procedures stipulated in the TSE application schedule. Contact:Masahiro NagayasuGeneral ManagerInvestor Relations+81-75-935-6140ir@nidec.com

Continue reading

Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Topline Results from Phase 2b ‘X-TOLE’ Clinical Trial of XEN1101

Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Topline Results from Phase 2b ‘X-TOLE’ Clinical Trial of XEN1101

BURNABY, British Columbia, Oct. 03, 2021 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that Xenon management will host a conference call and webcast to discuss topline results from the XEN1101 Phase 2b “X-TOLE” clinical trial on Monday, October 4, 2021 at 7:30 am Eastern Time. A conference call and webcast with slides will be broadcast live on the Investors section of the Xenon website. To participate in the call, please dial (855) 779-9075, or (631) 485-4866 for international callers, and provide conference ID number 4481713. The above listed dates and times are subject to change. When available, webcasts will be posted for replay following the event. About Xenon Pharmaceuticals Inc. We are a clinical stage biopharmaceutical company committed to developing...

Continue reading

Active Biotech: Tasquinimod clinical  development in multiple myeloma advances into combination therapy following completion of the initial phase of the ongoing trial in the US

Active Biotech: Tasquinimod clinical  development in multiple myeloma advances into combination therapy following completion of the initial phase of the ongoing trial in the US

Lund Sweden, October 3, 2021 – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announces that the ongoing trial of tasquinimod in multiple myeloma has reached an important milestone. Ten patients have been treated with increasing doses of tasquinimod, which was generally well tolerated. The optimal dose and schedule of tasquinimod, when used as a single agent in patients with multiple myeloma has been established at 1 mg per day after a one-week run in of 0.5 mg daily. This is similar to the treatment schedule used in previous studies of tasquinimod. The trial will now advance to a previously planned combination part, in which treatment with tasquinimod will be tested in patients with multiple myeloma together with the orally administered antimyeloma agents ixazomib, lenalidomide, and dexamethasone (IRd). Once an optimal dose and...

Continue reading

Festi hf.: Buy-back programme week 39

Festi hf.: Buy-back programme week 39

In week 39 Festi purchased in total 1,249,121 own shares for total amount of 264,106,620 ISK as follows: Week Date Time Purchased shares Share Price Purchase price 39 27.9.2021 14:12:41 150.000 208,000 31.200.000 39 27.9.2021 15:29:39 100.000 208,000 20.800.000 39 28.9.2021 13:10:48 150.000 208,000 31.200.000 39 28.9.2021 14:52:29 100.000 208,000 20.800.000 39 29.9.2021 10:42:20 100.000 206,000 20.600.000 39 29.9.2021 13:25:45 100.000 207,000 20.700.000 39 29.9.2021 15:12:09 50.000 210,000 10.500.000 39 30.9.2021 12:53:56 1.060 214,000 226.840 39 30.9.2021 12:59:30 1 214,000 214 39 30.9.2021 13:08:33 98.939 214,000 21.172.946 39 30.9.2021 13:09:10 150.000 214,000 32.100.000 39 1.10.2021 11:16:48 94.090 220,000 20.699.800 39 1.10.2021 12:31:01 1.500 220,000 330.000 39 1.10.2021 14:06:37 150.000 220,000 33.000.000 39 1.10.2021 14:33:44 3.531 220,000 776.820       1.249.121   264.106.620 Before...

Continue reading

Roper Technologies to Sell TransCore for $2.68 Billion

Roper Technologies to Sell TransCore for $2.68 Billion

SARASOTA, Fla., Oct. 03, 2021 (GLOBE NEWSWIRE) — Roper Technologies, Inc. (NYSE: ROP), a leading diversified technology company, today announced that it has reached a definitive agreement to divest its TransCore business to Singapore Technologies Engineering Ltd (“ST Engineering”), a global technology, defense, and engineering group, for $2.68 billion in cash. TransCore is expected to generate approximately $545 million of revenue and $135 million of EBITDA in 2021. Roper will retain its DAT and Loadlink network software businesses, which it acquired together with TransCore in 2004. “ST Engineering will be a great owner for TransCore and will support the business as it pursues the next phase of its innovative work in traffic management, tolling technology, and smart city infrastructure,” said Neil Hunn, Roper Technologies’ President...

Continue reading